Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
This scoping review systematically mapped the published and registered evidence on Thymosin Beta-4 (TB4) and the related synthetic peptide TB-500 in tissue healing, regeneration, and musculoskeletal repair. Searching PubMed, Europe PMC, and ClinicalTrials.gov through March 2026, the authors identified 1,772 records and included 80 studies after screening. Key findings include: (1) the evidence base is heavily skewed toward in vitro and animal (preclinical) designs rather than human trials; (2) most research has examined TB4, while direct evidence on TB-500 was limited to a single included study; (3) the most studied tissue categories were wound/skin/soft tissue, vascular/endothelial, and ocular/corneal, with the strongest human evidence concentrated in ocular and wound-healing contexts; and (4) musculoskeletal-specific tissues—such as tendon, ligament, muscle, cartilage, and intervertebral disc—were comparatively underrepresented. The authors concluded that while the literature supports interest in several repair-related biological pathways, it remains unevenly distributed and largely preclinical, and does not yet provide a robust human evidence base for musculoskeletal applications. Scoping reviews do not perform meta-analyses or quality appraisal of individual studies, which limits causal conclusions.
Why this grade: This is a scoping review (not a meta-analysis with quality appraisal), published as a preprint, mapping a predominantly preclinical literature with very limited direct human evidence—particularly for TB-500 and musculoskeletal indications.
Thymosin beta-4 (TB4) and the related compound commonly referred to as TB-500 are widely discussed in tissue healing and musculoskeletal medicine, but the scope and nature of the supporting literature remain unclear. We conducted a scoping review to map the evidence on TB4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair. PubMed, Europe PMC, and ClinicalTrials.gov were searched through March 2026. English-language in vitro, animal, human, and registered clinical trial sources directly evaluating TB4, TB-500, or included derivatives in repair-related contexts were eligible. Of 1772 records identified, 80 studies were included. The evidence base was weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500. The most common tissue categories were wound/skin/soft tissue, vascular/endothelial, ocular/cornea, and bone. Direct musculoskeletal tissue categories such as tendon, ligament, muscle, cartilage, and spine/intervertebral disc were comparatively sparse. Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study. Overall, the mapped literature supports the popular interest in several repair-related pathways but remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.